1
|
Tsao T, Beretov J, Ni J, Bai X, Bucci J, Graham P, Li Y. Cancer stem cells in prostate cancer radioresistance. Cancer Lett 2019; 465:94-104. [DOI: 10.1016/j.canlet.2019.08.020] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2019] [Revised: 08/29/2019] [Accepted: 08/30/2019] [Indexed: 01/08/2023]
|
2
|
D'Agostino GR, Di Brina L, Mancosu P, Franzese C, Iftode C, Franceschini D, Clerici E, Tozzi A, Navarria P, Scorsetti M. Reirradiation of Locally Recurrent Prostate Cancer With Volumetric Modulated Arc Therapy. Int J Radiat Oncol Biol Phys 2019; 104:614-621. [DOI: 10.1016/j.ijrobp.2019.02.041] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2018] [Revised: 02/08/2019] [Accepted: 02/21/2019] [Indexed: 12/18/2022]
|
3
|
Cuccia F, Mortellaro G, Serretta V, Valenti V, Tripoli A, Gueci M, Luca N, Lo Casto A, Ferrera G. Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes. Cancer Manag Res 2018; 10:5053-5060. [PMID: 30464605 PMCID: PMC6214338 DOI: 10.2147/cmar.s182016] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
Purpose This is a mono-institutional study of acute and late toxicities and early biochemical control of a retrospective series of 75 prostate cancer patients treated with moderate postoperative hypofractionation delivered by helical tomotherapy (HT). Patients and methods From April 2013 to June 2017, 75 patients received adjuvant (n=37) or salvage (n=38) treatment, delivering to prostate bed a total dose of 63.8 Gy (equivalent dose in 2-Gy fractions=67.4 Gy) using 2.2 Gy fractions. Whole-pelvis irradiation was performed in 63% of cases (median dose, 49.3 Gy; range, 48–55.1 Gy). Concurrent hormonal therapy was administered in 46% of cases. Common Terminology Criteria for Adverse Events (version 4.0) was adopted for acute and late genitourinary (GU) and gastrointestinal (GI) toxicity evaluations. Biochemical progression was defined as PSA level increase of ≥0.2 or more above the postoperative radiotherapy (RT) nadir. Results Acute GU toxicities were as follows: G1 in 46% and G2 in 4%, detecting no G≥3 events. For GI toxicity, we recorded G1 in 36% and G2 in 18%. With a median follow-up of 30 months (range, 12–58 months), we found late toxicity G2 GI in 6.6% and G≥2 GU in 5.3%, including two patients who underwent surgical incontinence correction. Acute GI≥2 toxicity and diabetes were found to be predictive of late GI≥2 toxicity (P=0.04 and P=0.0019). Actuarial 2- and 3-year biochemical recurrence-free survivals were 88% and 73%, respectively, for the entire population. Conclusion In our experience, moderate hypofractionated postoperative RT with HT was feasible and safe, with reports of low incidence of toxicity and promising biochemical control rates.
Collapse
Affiliation(s)
- Francesco Cuccia
- Radiation Oncology School, University of Palermo, Palermo, Italy, .,Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy,
| | | | - Vincenzo Serretta
- Section of Urology, Department of Surgical Oncological and Oral Science, University of Palermo, Palermo, Italy
| | - Vito Valenti
- Radiation Oncology School, University of Palermo, Palermo, Italy, .,Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy,
| | - Antonella Tripoli
- Radiation Oncology School, University of Palermo, Palermo, Italy, .,Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy,
| | - Marina Gueci
- Radiation Oncology School, University of Palermo, Palermo, Italy, .,Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy,
| | - Nicoletta Luca
- Radiation Oncology School, University of Palermo, Palermo, Italy, .,Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy,
| | - Antonio Lo Casto
- Radiation Oncology School, Section of Radiological Sciences, DIBIMED, Università degli Studi di Palermo, Palermo, Italy
| | | |
Collapse
|